[앵커]
The World Health Organization and WHO advisory group recommended that the COVID-19 vaccine developed by the multinational pharmaceutical company AstraZeneca and Oxford University in the UK, which is expected to be supplied by us in the near future, can be used by people over 65 and also in areas where the mutant virus has occurred.
At the recommendation of the advisory group, the plan of the international project’CoVax’ for the joint purchase and distribution of vaccines has gained momentum.
Reporter Kang Seong-ok reports
[기자]
The World Health Organization’s WHO Expert Strategic Advisory Group said, “Considering the totality of available evidence, it is recommended to use the AstraZeneca vaccine for people over the age of 65.”
While acknowledging the lack of vaccine efficacy data for the elderly over 65 years old, he explained that “the vaccination response of the elderly and the lower age group will be no different.”
The advisory group also recommended that it can be used in areas where the mutant virus has occurred.
Amid controversy that it has no effect on the elderly and the South African mutant virus, the WHO advisory group has adopted somewhat contradictory recommendations.
[알레한드로 크라비오토 / WHO 전략자문단그룹 의장 : 이 백신이 중증질환에 대한 효과가 제한적이라 할지라도 변이가 있는 지역에도 사용을 제한할 이유가 없습니다.]
At the recommendation of the advisory group, the plan of the international project’COVAX facility’ for the joint purchase and distribution of vaccines has gained momentum.
AstraZeneca is KOVAX’s primary vaccine supplier, and KOVAX plans to deliver 336 million doses of this vaccine to member countries in the first half of this year.
[숨야 스와미나탄 / WHO 수석 과학자 : 이번 아스트라제네카 백신에 대한 권고안은 매우 중요한 일입니다. 지금 상황에서 코백스 프로그램의 주요 백신이기 때문입니다.]
The WHO will make a decision in the middle of this month on the urgent use of the AstraZeneca vaccine, based on the advisory’s recommendations.
To date, the WHO has approved emergency use only for Pfizer-Bioentech vaccines.
This is YTN Kang Seong-ok.
[저작권자(c) YTN & YTN plus 무단전재 및 재배포 금지]